Mobile Logo in White

CPRIT awards UT Health San Antonio $3.4 million to increase HPV vaccination rates in Bexar County, develop transformative technologies targeting drug-resistant cancers

 

The University of Texas Health Science Center at San Antonio (UT Health San Antonio) received $3,395,970 in new academic research and prevention awards as part of the latest $98 million funding round announced on May 21 by the Cancer Prevention and Research Institute of Texas (CPRIT). The state agency, which focuses on funding evidence-based cancer research and prevention efforts, has now awarded $167 million to UT Health San Antonio since 2010.

Community-based intervention to increase HPV vaccination rates for adolescents in Bexar County

Erika L. Thompson, PhD, MPH, associate professor in the Department of Quantitative and Qualitative Health Sciences at The University of Texas School of Public Health San Antonio at The University of Texas Health Science Center at San Antonio, in collaboration with The University of Texas at San Antonio (UTSA), received a CPRIT prevention grant of $975,000 to fund a community-based intervention program to increase vaccination rates for the human papillomavirus (HPV) among adolescents in Bexar County. HPV can lead to several different types of cancers in men and women. Therefore, improving vaccination rates is an effective way to reduce cancer risk and help prevent HPV-related cancers.

Erika L. Thompson, PhD, MPH

The project will integrate and adapt the All for Them vaccination program, an evidence-based, culturally appropriate, bilingual initiative run by Paula Cuccaro, PhD, at UTHealth Houston School of Public Health for the delivery and coordination of the social marketing campaign. UT Health San Antonio’s School of Nursing will deliver the HPV vaccines. The team will  collaborate with community organizations and community health workers that work closely with underserved communities to administer community-wide vaccination services, including in after-school programs.

“The project’s focus on reaching underserved populations ensures that it addresses the most pressing barriers to vaccination,” Thompson said. “By increasing community demand for the HPV vaccine, improving access to vaccination services, and building trust in vaccine safety and efficacy, this intervention aims to make meaningful progress toward reducing HPV-related cancer incidences and mortality in Texas.”

”With The UT School of Public Health San Antonio being among the newest schools of public health in Texas, we are proud of Dr. Thompson and team receiving these CPRIT funds to support their ongoing work,” said Tracey Barrnett, PhD, associate professor and chair in the Department of Quantitative and Qualitative Health Sciences. “This project represents public health in action, working with local community organizations to deliver science-based solutions for cancer prevention for all Texans.”

Develop transformative technologies that better target drug-resistant cancers

Daohong Zhou, MD, tenured professor in the Department of Biochemistry and Structural Biology in the Joe R. and Teresa Lozano Long School of Medicine, received CPRIT’s academic research award of over $2.4 million to expand UT Health San Antonio’s core facilities laboratories to increase researchers’ capabilities to better identify therapeutic targets and develop technologies to target hard-to-treat cancers.

Daohong Zhou, MD

Zhou, who serves as the director of the Target Discovery Core at the Greehey Children’s Cancer Research Institute at UT Health San Antonio, associate director for drug development at the Mays Cancer Center at UT Health San Antonio and director of the institution’s Center for Innovative Drug Discovery, shared that while there has been significant progress in treating cancers, we are still facing big challenges, especially with certain tough-to-treat pediatric and adult cancers like brain tumors, soft tissue sarcomas and those that do not respond well to current therapies.

“However, the absence of core facilities for target identification and validation (TIV) in Texas has limited the success in discovering and developing new cancer therapeutics because TIV is essential for drug discovery and development,” Zhou said. “In addition, the CPRIT award will allow us to acquire and develop new TIV technologies, including the state-of-the-art arrayed CRISPR knockout screening for TIV and groundbreaking small molecule degrader (SMD) discovery platform for screening SMDs to target undruggable proteins, which are not available in any other core facilities in Texas.”

Research impact in Texas and beyond

“Our researchers receiving highly competitive awards, such as CPRIT, to improve the lives of Texans, is a testament to the excellence of UT Health San Antonio’s research enterprise and demonstrates the extraordinary science conducted here,” said Jennifer Sharpe Potter, PhD, MPH, UT Health San Antonio senior vice president for research. “CPRIT is the largest state cancer research investment in the United States and the second largest cancer research and prevention program in the world. This recognition spotlights UT Health San Antonio’s ability to attract top-tier talent, which drives pioneering discoveries and advances health innovation on an international scale.”

The University of Texas Health Science Center at San Antonio is a world-class research university that was recently awarded the prestigious Research 1 (R1) designation by the American Council on Education and the Carnegie Foundation for the Advancement of Teaching in their 2025 Carnegie Classifications of Institutions of Higher Education. This designation firmly establishes UT Health San Antonio among the nation’s elite research universities, ranking it in the top 5% of U.S. institutions and underscores its prominent role in groundbreaking biomedical research and advancing medical education.



Share This Article!
Categories:
Secured By miniOrange